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Abstract. Childhood bone cancer though rare, has very limited treatment choices, 
with poor survival rates and often involving amputation. We have developed a novel 
molecule, 2', 4'-dihydroxy-dithion-dibenzoyl-methane and tested it on hepatic, colon, 
lung and osteoblasts cancer cell lines. Thionylation of 2', 4'- 
dihydroxydibenzoylmethane led to selective targeting of bone cancer cells, stopping 
their growth and leading to their death without affecting non-cancerous cells within 
the bone marrow or other non-malignant cells.  
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Cancer in bones can be either primary (initiated in the bones) or secondary (has 
spread to the bones) in nature. In primary bone cancer, osteosarcoma can affect any 
bone in the skeleton, though the femur, tibia and humerus are most commonly 
affected. Osteosarcoma accounts for about 3% of cancer in children, especially 
during early adolescence when bone growth is at its peak (1). Ewing’s sarcoma 
affects mainly teenagers and has an incidence of 34% among all bone cancer. It 
appears mainly in the pelvis, thigh and shin areas, although this type of tumour can 
also occur in soft tissues (soft-tissue sarcoma) (2). Rare forms of bone cancer 
account for the remaining 6% of bone cancer in children (3).  Other primary bone 
cancer that affect mainly adults over 40 years old, are chondrosarcoma in hips, legs, 
arms and shoulders; several variations of spindle-cell sarcoma; and chordoma in 
lungs, nearby bones, lymph nodes, liver and skin. Secondary cancer can arise from 
primary tumours spreading to other tissues and the most prevalent tumours resulting 
from secondary bone cancer are those of the prostate, breast, lung, kidney and 
thyroid. 
 Survival rate after treatment depends highly on a patient’s age at the time of 
diagnosis, and the stage and type of bone cancer. In teenagers with Ewing’s 
sarcoma, survival rate after treatment ranges from 20 to 70% over 5 years, but  is 
dependent on the site and size of the tumour (4-7). Treatment generally involves 
some type of surgery, and the stage of the cancer will determine which type of 
surgery will be used. It can vary from removing only the area affected in the bone to 
amputation of the limb. Further treatment can include radiotherapy and 
chemotherapy (8-10). Osteosarcomas can be treated with doxorubicin (a DNA 
intercalator), methotrexate (an antimetabolite) and cisplatin (a DNA alkylator). 
Ewing’s sarcoma requires a mixture of drugs, including cocktail 1 consisting of 
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vincristine (antimitotic agent), ifosfamide (DNA alkylator), doxorubicin, and etoposide 
(topoisomerase II inhibitor). This is followed by cocktail 2 made up of vincristine, 
ifosfamide and actinomycin D (DNA groove binder) with/without cocktail 3, which is a 
mixture of vincristine, actinomycin D and cyclophosphamide (DNA alkylator). 
Treatment of bone cancer with small molecules can be effective depending on the 
type of cancer and stage. However, there are side-effects which affect the outcome 
for the patient. This can affect the rate of remission, produce delays in recovery 
times or cause long-term effects such as fertility problems (11-16). Biological 
therapies are currently being evaluated in clinical trials, with the aim of identifying 
new molecules (generally antibodies or adjuvants) which encourage the immune 
system to attack the cancer cells by recruiting immune-modulators such as tumour 
necrosis factors (TNFs) and interferons.  
 Dibenzoyl-methane derivatives (DBMD) (1; Figure 1) have been found in 
green tea leaves from Camellia sinensis and have been used in traditional medicine 
to treat several conditions, ranging from infection to rheumatic diseases, and as 
antioxidants. Their biological activity has not been completely elucidated, but studies 
in other cell lines indicate activities in p53, retinoblastoma, and mitochondria (17-20). 
 
Generation of DBMD derivatives. We employed the improved Baker–Venkatarman 
arrangement (21),  (Figure 2) to produce five dibenzoyl-methane derivatives: 2’,4’-
dihydroxy-dibenzoyl-methane (1), 2’-hydroxy-4’amino-dibenzoyl-methane (2) , 2’,4’-
dihydroxy3’’methoxy-dibenzoyl-methane (3), and 2’,4’-dihydroxy4’’methoxy-
dibenzoyl-methane (4). Thionylation of 2’,4’-dihydroxy-dibenzoyl-methane produced 
2’,4’-dihydroxy-dithiodibenzoyl-methane (DBM-S, 5),  (Figure 3). 
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 This article describes the development a novel molecule, 2', 4'dihydroxy-
dithiondibenzoyl-methane and derivatives thereof and highly promising results 
obtained for cell viability in applying it against hepatic, colon, lung and osteoblasts 
cancer cell lines with subsequent in-depth studies in osteoblasts. 
 
Materials and Methods  
Materials. A combination of compounds were obtained from various suppliers. Alfa 
Aesar, Heysham, Lancashire UK: 3', 4', 5'Trimethoxyacetophenone, benzoyl 
chloride, 3-methoxybenzoyl chloride, Lawesson's reagent. TCI Tokyio Kasei, 
Birkenhead UK:2', 4' Dihydroxyacetophenone, 4-Methoxybenzoyl chloride. 
Fluorochem, Hadfield, Derbyshire, UK: Potassium tert-butoxide and silica gel (60 Å). 
Thermo Fisher Scientific, Altrincham, Greater Manchester, UK: 4-Amino-2-
hydroxyacetophenone, anhydrous tetrahydrofuran (THF), hydrochloric acid, toluene, 
ethyl acetate, petroleum ether, ethanol, hexane, dimethylsulfoxide (DMSO), foetal 
bovine serum (GIBCO), RPMI-1640 (Roswell Park Memorial Institute Medium) 
(HyClone), 0.05% Trypsin-EDTA (GIBCO), sterile  phosphate-buffered saline 
(sPBS), tetramethylsilane (TMS). VWR West Sussex, UK: TLC (Thin layer 
chromatography) silica gel 60 F245 (Merck). Cambridge Isotope Laboratories, 
Tewksbury, MA, USA: Deuterated chloroform (CDCl3). Sigma-Aldrich, Dorset UK: L-
Glutamine 100x, Minimal Essential Media (MEM) non-essential amino acid 100x, 
penicillin-streptomycin 100x, chlorpromazine hydrochloride, 3(4,5-dimethylthiazol-2-
yl)2,5-diphenyl-tetrazolium bromide (MTT) and Saos2 cell line. University of Salford 
Cell Bank, Salford, Greater Manchester UK: HCT116 and A549 cell lines. Cyprotex, 
Macclesfield, East Cheshire UK: HepG2 cell line. Eurofin, Manchester, Manchester 
UK: oligonucleotides. Accurate mass spectrometry was performed in a liquid 
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chromatography mass spectrometer (LCMS)  Agilent 6540 accurate mass quadruple 
time-of-flight, (Yanton, Oxford, UK). Infra-red (IR) analysis was performed in a 
NicoletTMIsTM50 FT-IR attenuated total reflectance (ATR) (Thermo Fisher Scientific, 
Altrincham, Greater Manchester, UK). 1H (proton) and 13C (carbon) nuclear magnetic 
resonance (NMR) was performed in a Bruker TOPSPIN 400 MHz (Coventry, UK) 
using TMS as control. 
 
Synthesis. 2',4'-Dihydroxy-dibenzoyl-methane (1): Under argon, 1-(4amino-2-
hydroxy-phenyl)-ethanone (6.57  mmol, 1.0 g) dissolved in anhydrous THF (20 ml) 
was added dropwise to a cooled (0 ͦC) solution of KOtBu (10.51 mmol, 1.18 g) in 
anhydrous THF (50 ml). The solution was then stirred at room temperature for 1 h, 
then chilled to 0°C before benzoyl chloride (6.57 mmol, 0.762 ml) was added 
dropwise and stirred at room temperature for 1 h, before being cooled (0°C) , to 
which KOtBu (10.51 mmol, 1.18 g) was added and then stirred at room temperature 
for 15 min, followed by 24 h under reflux. The product was extracted by the addition 
of 0.5M HCl (100 ml) producing a light yellow precipitate, which was then 
recrystallized with ethanol to yield yellow needles. Yield: 51.2%. Yellow solid. Melting 
point: 158-161°C.1H NMR (CDCl3, TMS, 300 MHz): δ = 3.4 (s, 1H), 4.6 (s, 1H), 6.8 
(s, 1H), 6.9-8.3 (m, 8H), 11.7 (s, 1H), 12.4 (s, 1H), 15.5 (s, 1H). 13C NMR (CDCl3, 
TMS, 300 MHz): δ = 63.22, 98.73, 101.3, 102.79, 121.18, 121.42, 123.66, 125.56, 
125.84, 126.87, 127.58, 158.05, 159.74, 197.66, 189.22. FT-IR (ATR) (cm-1): 3060, 
1741, 1621, 1588, 1497, 1452, 1430, 1298, 1236, 1205. LC-MS m/z: 255.0654(M-
H)-1 
 2'Hydroxy,4'aminodibenzoylmethane (2): Under argon, 2-hydroxy-4-amino-
dibenzoyl-methane (1.32 mmol, 0.2 g) dissolved in anhydrous THF (8 ml) was added 
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dropwise to a cooled mixture (0°C) of KOtBu (2.11 mmol, 0.24 g) in anhydrous THF 
(15 ml). The solution was then stirred at room temperature for 1 h. The reaction was 
then re-cooled (0°C) to which benzoyl chloride (1.32 mmol, 0.154 ml) was added 
dropwise, and then stirred at room temperature for further 1 h. The reaction was 
cooled to (0°C) before KOtBu (2.11 mmol, 0.24 g) was added and the mixture stirred 
at room temperature for 15 min, followed by reflux for 24 h. The product was 
extracted by the addition of 0.5M HCl (100 ml), producing a brown yellow precipitate, 
which was then recrystallized with ethanol to yield yellow needles and purified by 
flash chromatography [silica, petroleum ether (40-60): ethyl acetate]. Yield: 46.3%. 
Yellow solid. Melting point: 110-112°C. 1H NMR (CDCl3, TMS, 300 MHz): δ = 4.6 (s, 
1H), 5.3 (s, 2H), 6.8 (s, 1H), 6.9-8.2 (m, 8H), 11.8 (s, 1H), 12.4 (s, 1H), 15.5 (s, 1H). 
13C NMR (CDCl3, TMS, 300MHz): δ = 26.41, 92.13, 108.14, 115.44, 127.14, 128.50, 
129.92, 132.13, 133.68, 134.38, 144.66, 163.83, 163.88, 176.87, 194.45. FT-IR 
(ATR) (cm-1) 3496, 3370, 1671, 1602, 1572, 1508, 1488, 1456, 1358, 1270, 1218, 
1191, 1151, 1043. LC-MS m/z: 254.0818 (M-H)-1.  
 2',4'-Dihydroxy-3''-methoxy-dibenzoyl-methane (3): Under argon, 2',4'-
dihydroxy-acetophenone (6.57 mmol, 1.0 g) was dissolved in anhydrous THF  (20 
ml) and then added dropwise to a cooled solution (0°C) of KOtBu (10.51 mmol, 1.18 
g) in anhydrous THF (50 ml), followed by stirring at room temperature for 1 h. The 
reaction was then cooled (0°C) before 3-methoxybenzoyl chloride (6.57 mmol, 0.923 
ml) was added dropwise and then stirred at room temperature for a further 1 h. The 
mixture was cooled (0°C) before KOtBu (10.51 mmol, 1.18g) was added and then 
stirred at room temperature for 15 min, then refluxed for 24 hours. The product was 
extracted by the addition of 0.5 M HCl (100 ml), producing a light yellow precipitate, 
then recrystallized with ethanol to yield yellow needles and purified by flash 
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chromatography [silica, petroleum ether (40-60): ethyl acetate].  Yield: 47.1%. Yellow 
solid. Melting point: 110-112°C. 1H NMR (CDCl3, TMS, 300MHz): δ = 3.5 (s, 1H), δ 
3.9 (s, 3H), 4.6 (s, 1H), 6.8 (s, 1H), 6.9-8 (m, 7H), 11.8 (s, 1H), 12.4(s, 1H), 15.5(s, 
1H). 13C NMR (CDCl3, TMS, 300MHz): δ = 55.53, 92.50, 113.15, 114.55, 119.21, 
120.51, 129.75, 130.24, 134.92, 163.96, 164.22, 177.36, 194.72. FTIR (ATR) (cm-1) 
2834, 1741, 1612, 1583, 1504, 1489, 1451, 1320, 1282, 1042, , LC-MS m/z: 
285.0763 (M-H)-1.  
 2',4'-Dihydroxy-4''-methoxy-dibenzoyl-methane (4). Under argon, 2',4'-
dihydroxy-acetophenone (6.57 mmol, 1.0 g) was dissolved in anhydrous THF  (20 
ml) was added dropwise to a cooled solution (0°C) of KOtBu (10.51 mmol, 1.18 g) in 
anhydrous THF (50 ml), followed by 1 h of stirring at room temperature. The solution 
was cooled to 0°C before 4-metoxybenzoyl chloride (6.57 mmol, 0.89 ml) was added 
dropwise, and then stirred at room temperature for a further 1 h. The reaction was 
cooled again (0°C) before adding KOtBu (10.51 mmol, 1.18g) followed by reflux for 
24 h.  The product was extracted by the addition of 0.5 M HCl (100 ml); a light yellow 
precipitate was formed, then recrystallized with ethanol to yield yellow needles and 
purified by flash chromatography [silica, petroleum ether (40-60): ethyl acetate]. 
Yield: 51.3%. Yellow solid. Melting point: 137-141°C. 1H NMR (CDCl3, TMS, 
300MHz): δ = 4.6 (s, 1H), 6.75 (s, 1H), 3.5 (s, 1H), 3.9 (s, 3H) 6.8-8.3 (m, 7H), 11.8 
(s, 1H), 12.4(s, 1H), 15.5(s, 1H). 13C NMR (CDCl3, TMS, 300MHz): δ= 26.33, 55.40, 
102.24, 108.07, 112.82, 113.77, 122.91, 131.30, 133.69, 164.16, 166.96, 202.68. 
FT-IR (ATR) (cm-1) 3475, 1727, 1606, 1509, 1257, 1241, 1185, 1044, 1026. LC-MS 
m/z: 285.0764 (M-H)-1. 
 1(-2',4'-Dihydroxy-phenyl)-3-phenylpropane-1,3-dithion (5): Lawesson’s 
reagent (1.17 mmol) was added to (2',4'dihydroxy benzoyl)-methane (1.95 mmol, 0.5 
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g) dissolved in toluene (25 ml). The reaction was then refluxed for 24 hours. The 
solvent was removed using reduced pressure and the crude product was purified by 
preparative TLC (petroleum ether: ethyl acetate). Yield: 60.7%. Red solid.  Melting 
point: 165-167°C. 1H NMR (CDCl3, TMS, 300MHz): δ = 3.3 (s, 1H), 5.3 (s, 2H), 6.9-
8.5 (m, 8H). 13C NMR (CDCl3, TMS, 300MHz): δ = 63.22, 98.73, 101.3, 102.79, 
121.18, 121.42, 123.66, 125.56, 125.84, 126.87, 127.58, 158.05, 159.74, 189.22, 
197.66. FT-IR (ATR) (cm-1) 2926, 2369, 1646, 1597, 1576, 1448, 1378, 1223, 1118. 
LC-MS m/z: 575.0751 (2M-H)-1.  
 
Cell culture. Cells (HepG2, A549, HCT116 and Saos2) were grown as an adherent 
monolayer culture in 75 cm2 flasks in RPMI-1640 medium supplemented with 10% 
heat inactivated foetal bovine serum (FBS), 1% v/v nonessential amino acids, 2 mM 
L-glutamine and 115 units/ml of penicillin G, and 115 μg/ml of streptomycin at 37°C 
under a humidified atmosphere containing 5% CO2 and 95% air.  
 
MTT assay. The five compounds were tested at a range of concentrations (range=0-
100 μM) and cell death percentage was determined by the colorimetric MTT micro-
culture assay. Cells were detached from the 75 cm2 flasks (at a confluence of 70%) 
by trypsinization, and seeded in 100 μl aliquots into 96-well clear micro-culture 
plates. Cells (HepG2, A549, HCT116 and Saos2) at density of 3.0 × 103 cells/well 
were incubated for 72 hours in order to ensure exponential growth of untreated 
controls throughout the experiment. Cells were allowed to adhere to the 96-well 
micro-culture plate for 24 h prior to dosing. Stock solutions of the test compounds in 
DMSO were appropriately diluted in complete culture medium to make up the 
required concentrations, and then added in 25 μl aliquots to the 96-well micro-culture 
10 
 
plate. Cells were exposed to the test compounds for 72 h. Plates were maintained at 
37°C in a humidified atmosphere containing 95% air and 5% CO2. At the end of the 
incubation period, 30 μl/well MTT solution in sPBS (3 mg/ ml) were added, and then 
plates incubated for a further 3 h. After the end of the incubation, the supernatants 
containing the medium and MTT were removed and the formazan crystals formed by 
viable cells were dissolved in 100 μl of DMSO per well. Optical densities at λ = 540 
nm were measured with LUMIistar Omega multi-mode plate reader (Edinburgh, UK). 
The colorimetric MTT assay was used to determine the cell death percentage at 
serial diluted concentrations of the tested compounds and the concentration at which 
50% of cell growth was inhibited (IC50) as compared to the control wells which did 
not contain any drug was determined from a dose–response curve using OriginPro 
9.1 (Northampton, MA, USA) data analysis and graphing software. Chlorpromazine 
was used as positive control in the MTT assay. Data were collected as duplicates 
and statistical analysis calculated as standard deviation (SD) using Excel Microsoft 
(Reading, Berkshire, UK). 
 
Caspase assay.  2', 4'-Dihydroxydithiondibenzoylmethane was tested at a range of 
concentrations (range=0-5-10 and 20 μM) and caspase activity was determined by 
using an ApotoxGlo® (Promega. Madison, WI, USA) assay. Cells (HepG2, A549, 
HCT116 and Saos2)  were detached from the 75 cm2 flasks (at a confluence of 70%) 
by trypsinization, and seeded in 100 μl aliquots into 96-well clear micro-culture 
plates. Cells were allowed to adhere to the 96-well micro-culture plate for 24 h prior 
to dosing. Stock solutions of the test compounds in DMSO were appropriately diluted 
in complete culture medium to make up the required concentrations, and then added 
in 25 μl aliquots to the 96-well micro-culture plates. Cells were then incubated for 24, 
11 
 
48 and 72 h at densities of 5, 4 and 3.0 × 103 cells/wells, respectively. Plates were 
maintained at 37°C in a humidified atmosphere containing 95% air and 5% CO2. At 
the end of the incubation period, 20 μl/well of the part 1 ApotoxGlo® was added and 
after 30 min of incubation at 37ºC cell viability was read at 404 excitation / 520 
emission with LUMIistar Omega multi-mode plate reader. Caspase assay was 
performed by adding part 2 of the ApotoxGlo® as 100 μl/well and incubating for 30 
min at room temperature. The luminescence was read using the same plate reader 
in luminescence mode. The data were analysed and normalised to those of the 
vehicle control (DMSO). Data were collected as duplicates and statistical analysis 
calculated as SD using Microsoft Excel. 
 
Cell-cycle analysis. Cell-cycle analysis was performed using a modified protocol 
described by Larson et al. (22). Briefly, Saos2 cells were treated with DMSO or 2',4'-
dihydroxydithiondibenzoylmethane for 48 h, and thereafter cells were treated with 
Trypsin/EDTA for 10 min at 37°C. Re-suspended cells were fixed with 500 µl 
formaldehyde (4% formaldehyde in PBS) and incubated at 4°C for 20 min. Cells 
were centrifuged at 400 ×g for 10 min and the pellet was washed in 1  ml PBS. The 
pellet of cells was re-suspended in 50 µl RNAase solution and incubated at room 
temperature for 30 min. The cells were washed again by adding PBS and 
centrifuged. DNA was stained with 50 µl propidium iodide (50µg/ ml, Sigma Aldrich). 
The samples were then incubated at room temperature for 15 min in the dark and 
analysed by FACSVerse, BD Biosciences, San Jose, CA, USA. The results were 
analysed using BD FACSuite software (BD Biosciences). Data were collected as 
duplicates and statistical analysis calculated as SD 
 using Microsoft Excel. 
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Quantitative RT PCR. RNA was extracted from Saos2 cells using RNAeasy mini kit 
(Qiagen, Manchester, UK) as per manufacturer’s instructions. Total RNA was used 
to generate first-strand complementary DNA by the following reaction: 2 µg of total 
RNA,4 µl MgCl2 (25 mM stock), 2 µl of 10× First-Strand buffer, 2 µl of dNTP Mix (10 
mM stock), 1 µl of Random Hexamers (500 mg/ml stock), 0.2 µl RNAse OUT and 0.2 
µl of SuperScriptiII reaction volume was made up to a total of 20 µl with deionised 
water. This mixture was first incubated for 10 min at 65°C and subsequently at 45°C 
for 1 h. The reaction was then stopped by increasing the temperature to 85°C for 15 
min. Quantitative RT-PCR was performed on cDNA using AP BioSystems 7500 
Thermal cycler using Syber Green (Thermo Fisher Scientific, Altrincham, 
Manchester, UK) relative quantitative method described earlier (23). The following 
primer sets were used for quantification: HPRT gene was served as internal control 
(F-GAGGAGTCCTGTTGATGTTGCCAG and R-
GGCTGGCCTATAGGCTCATAGTGC), CDK4 (F-ATGGCTACCTCTCGATATGAGC 
and R-CATTGGGGACTCTCACACTCT), CDK6 (F-GCTGACCAGCAGTACGAATG 
and R-GCACACATCAAACAACCTGACC). Data were collected as duplicates and 
statistical analysis calculated as SD using Microsoft Excel. 
 
Results and Discussion 
Chemical synthesis. A new family of dibenzoyl-methane derivatives were 
synthesised as a one-pot reaction, in which an acylated phenol ester is formed from 
the reaction of a substituted acetophenone with benzyl chloride to yield a phenol 
ester, which then underwent a base-induced Baker–Venkatarman rearrangement to 
yield the wanted aromatic1,3-diketone. The thionylation of the 1,3-diketone of 2',4'-
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dihydroxy-dithiodibenzoyl-methane was performed using Lawesson’s reagent. The 
compounds were purified using flash chromatography and then fully characterised 
(accurate MS, NMR and IR). The two carbonyl oxygens on the dibenzoyl-methane 
derivatives are known to undergo hydrogen bonding; this was observed in the proton 
NMR at higher than 10 ppm. All the starting materials are very economic hence the 
compounds were produced at a reduced cost, which is important when producing 
larger quantities for therapeutic purposes. 
 
Biological activity. Saos2 (osteogenic sarcoma) is a bone cancer cell line derived 
from the primary osteosarcoma of an 11-year-old Caucasian girl. This cancer cell 
line possesses several osteoblastic features that make it extremely useful as a 
permanent line of human osteoblast-like cells for drug discovery and as a source of 
bone-related molecules (24). We tested all five compounds on HepG2 (childhood 
liver cancer), HCT116 (adult colonic cancer), A549 (adult lung cancer) (and Saos2 
(childhood osteoclast) cell line for 72 h (Table I). 2’,4’-Dihydroxy-benzoyl-methane 
and 2’,4’-dihydroxy-3’’-methoxy-benzoyl-methane had similar activity against all the 
cell lines at IC50 of 4 to 10 μM for at 72 h of incubation. The amino substituent in 2’-
hydroxyl-4’amino-benzoyl-methane produced loss of activity by a factor of 5 against 
HepG2, HCT116 and A549 cells with an  IC50 approaching 20 μM. However, this 
compound showed a clear preference for toxicity towards Saos2 cells. From this 
group with hydroxyl and methoxy substitutions, 2’,4’-dihydroxy-4’’-methoxy-benzoyl-
methane presented high activity, with an  IC50 at around 4 μM, but exhibited no 
selectivity for the cell lines. From our five compounds, the thionylated 1-(2',4'-
dihydroxyphenyl)-3-phenylpropane1,3-dithion had poor activity against HepG2 and 
A549 cells (IC50 of 33.43 and 43.54 μM respectively), moderate activity  against 
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HCT116 cells (IC50 of 13.17 43.54 μM) and a strong selective activity against Saos2 
cells (IC50 of 4.33 μM). We observed this compound was between 3 and 10 times 
more selective for the Saos2 childhood osteoclast cell line. Chlorpromazeine acted 
as positive control, presenting IC50 values in the range of 5-11 μM. 
 Apoptosis is a form of programmed cell death and is caspase-dependant, 
which is a safeguard mechanism protecting the organism while sacrificing the 
individual cell. Some drugs, such as doxorubicin and dactinomycin, are activators of 
the caspase pathway; caspase activation can appear in the very early stages, and 
sometimes this can be mistaken for necrosis (25). However, other pathways of cell 
death are also possible in which caspases are not activated. These can include: 
autophagy, paraptosis, mitotic catastrophe, and the descriptive model of apoptosis-
like and necrosis (26, 27). Drugs with cytotoxic properties can trigger necrosis as 
death stimulus, with features such as disrupted cell membrane, destruction of 
organelles, swelling and then shrinking of the cell, and with the toxic waste being 
dispersed within the surrounding cells (28, 29). These caspase-independent 
mechanisms can be produced by reactive oxygen species produced by external 
stimuli in the mitochondria (30). This mechanism can be activated by molecules 
interacting with the T-cell/interferon/Toll-like/TNF superfamily receptors (31) and 
various anticancer molecules such as ionomycin (32) and catechins from green tea, 
(33). 
 In a bid to identify a mode of action of our molecules, we employed the 
ApoToxGlo® (Promega) assay for assessing the mode of action. The caspase assay 
is composed of a substrate (proluminescent caspase-3/7 DEVD-aminoluciferin) 
which is cleaved and the free aminoluciferin is reacted by the luciferase, producing a 
luminescent signal proportional to the caspase-3/7 activity (34). We tested DBM-S at 
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5, 10 and 20 µM for 24, 48 and 72 h and normalised the data to those of the vehicle 
control DMSO. The results indicate DBM-S reduced caspase activity steadily as the 
concentration used increased (Table II). At an exposure of 24 h, the caspase activity 
was reduced by between 30-40%, at 48 hours it was reduced to around 50% and for 
a longer exposure of 72 h the activity was similar to that of the 1-day exposure as the 
level of activity was around 60%.  
 Cell division is regulated in an elaborate fashion to coordinate cell growth with 
DNA replication.  The cell cycle is a series of events in which the cells synthesise 
DNA, proteins and all the materials needed to produce two daughters. This vital 
process is subdivided in four distinct phases, gap 1(G1), synthesis (S), gap 2 (G2) 
and mitosis (M), each of which is under strict control of protein called cyclins and 
cyclin-dependant kinases (CDK). Complexes of cyclins with CDKs trigger the 
progression of the cell cycle, where cyclins act as regulatory subunits and the CDKs 
are the catalytic subunits. When both are activated and bound, through 
phosphorylation, this coordinates the cell’s next step (35). Selectively blocking cell-
cycle progression is an effective treatment for many types of cancer by arresting 
their development (36, 37).     
 We studied the cell-cycle progression of the Saos2 cell line in the presence 
and absence of DBM-S. Cell-cycle analysis showed that within 48 h of treatment, 
proliferation of Saos2 cells was significantly reduced, with a concomitant increase in 
subG1-phase cells, indicating significant apoptosis (Figure 4). Treatment with DBM-S 
induced cell-cycle arrest indicating disruption of the cell-cycle control mechanism. To 
evaluate this further, we analysed the relative mRNA expression levels of CDK4 and 
CDK6 along with transcription factor MYC that controls the expression of cyclins with 
internal housekeeping control gene using HPRT1 (Figure 5). Expression of the proto-
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oncogene cMYC is known to be correlated with cell-cycle progression, with it being 
very low in non-proliferating cells and highly expressed when cells are to progress to 
S phase from G1 (38,39). In addition, MYC is known to directly activate transcription 
of CDKs and hence plays a major role in cancer progression (40-41). Quantitative 
PCR results indicated that MYC mRNA levels were greatly reduced within 48 h of 
drug treatment. Moreover, CDK4 and CDK6 mRNA expression levels were also 
significantly reduced. This shows this novel compound arrested the cells, stopping 
them from dividing. Such reduction in mRNA levels might be a direct effect of drug 
treatment or the consequence of apoptosis triggered by DBM-S. 
 
 
Conclusion 
Treating cancer in children aggressively is the best option for continued health, 
despite the risk that side-effects can arise years later. Sometimes sequelae 
from surgery can also diminish subsequent quality of life. Producing new 
selective and effective anticancer agents has become a goal for many 
laboratories which are now focusing their resources in this direction to achieve 
that aim.  Here we used classic organic reactions to produce a family of 
dibenzoyl-methane derivatives with promising anticancer activities. Using 
established organic methods, we very cheaply produced five compounds that 
were tested for anticancer activity on different cell lines including hepatic, 
colon, lung and osteoblast cancer. Although all compounds showed some 
degree of activity against the cancer cell lines, DBM-S produced the most 
promising and interesting results. This novel compound, tested on different 
types of cancer cells, was shown to be very selective for osteoblasts, which 
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could lead to the deduction that this compound would produce fewer 
gastrointestinal side-effects; this property can be exploited in formulation 
studies. It is possible that primary necrosis is the mechanism inducing cell 
death of Saos2 cells, however, sub-G1 cell accumulation indicates DNAse 
activation, which is considered a feature of apoptosis and this could be a very 
early stage in a multi-pathway activity. G1 arrest of Saos2 cells also indicates a 
block in cell-cycle progression consistent with inhibition of CDKs as a 
mechanism of action. Although more work will follow, this novel thionylated 
compound based on dibenzoyl-methane opens the possibility of studies for 
combination therapy in order to achieve less toxic side-effects during the 
treatment of bone cancer. 
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